223 related articles for article (PubMed ID: 35332790)
1. All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States.
Mostaghimi A; Gandhi K; Done N; Ray M; Gao W; Carley C; Wang T; Swallow E; Sikirica V
J Manag Care Spec Pharm; 2022 Apr; 28(4):426-434. PubMed ID: 35332790
[No Abstract] [Full Text] [Related]
2. Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata.
Ray M; Swallow E; Gandhi K; Carley C; Sikirica V; Wang T; Done N; Signorovitch J; Mostaghimi A
J Health Econ Outcomes Res; 2022; 9(2):11-18. PubMed ID: 35975139
[No Abstract] [Full Text] [Related]
3. Comparing the burden of illness in patients with alopecia areata vs atopic dermatitis in the US population from a payer perspective.
Fenske DC; Ding Y; Morrow P; Smith SG; Silver MK; Moynihan M; Manjelievskaia J
J Manag Care Spec Pharm; 2023 Apr; 29(4):409-419. PubMed ID: 36989453
[No Abstract] [Full Text] [Related]
4. Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population.
Mostaghimi A; Gao W; Ray M; Bartolome L; Wang T; Carley C; Done N; Swallow E
JAMA Dermatol; 2023 Apr; 159(4):411-418. PubMed ID: 36857069
[TBL] [Abstract][Full Text] [Related]
5. Overview of alopecia areata for managed care and payer stakeholders in the United States.
King B; Pezalla E; Fung S; Tran H; Bourret JA; Peeples-Lamirande K; Takiya L; Napatalung L
J Manag Care Spec Pharm; 2023 Jul; 29(7):848-856. PubMed ID: 37219075
[TBL] [Abstract][Full Text] [Related]
6. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
7. Prevalence of autoimmune and inflammatory diseases and mental health conditions among an alopecia areata cohort from a US administrative claims database.
George P; Jagun O; Liu Q; Wentworth C; Napatalung L; Wolk R; Anway S; Zwillich SH
J Dermatol; 2023 Sep; 50(9):1121-1128. PubMed ID: 37291688
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
[No Abstract] [Full Text] [Related]
9. Treatment Patterns for Alopecia Areata in the US.
Lee H; Huang KP; Mostaghimi A; Choudhry NK
JAMA Dermatol; 2023 Nov; 159(11):1253-1257. PubMed ID: 37728940
[TBL] [Abstract][Full Text] [Related]
10. Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims.
Senna M; Ko J; Tosti A; Edson-Heredia E; Fenske DC; Ellinwood AK; Rueda MJ; Zhu B; King B
Adv Ther; 2021 Sep; 38(9):4646-4658. PubMed ID: 34292518
[TBL] [Abstract][Full Text] [Related]
11. Annual costs among patients with major depressive disorder and the impact of key clinical events.
Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
[No Abstract] [Full Text] [Related]
12. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
Xing S; Batt K; Kuharic M; Bullano M; Caicedo J; Chakladar S; Markan R; Farahbakhshian S
J Manag Care Spec Pharm; 2023 Jun; 29(6):626-634. PubMed ID: 37276033
[No Abstract] [Full Text] [Related]
13. Direct health care costs associated with COVID-19 in the United States.
DeMartino JK; Swallow E; Goldschmidt D; Yang K; Viola M; Radtke T; Kirson N
J Manag Care Spec Pharm; 2022 Sep; 28(9):936-947. PubMed ID: 35722829
[No Abstract] [Full Text] [Related]
14. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
[No Abstract] [Full Text] [Related]
15. The economic burden of HIV-associated wasting in the era of modern antiretroviral therapy.
Siddiqui J; Samuel SK; Hayward B; Wirka KA; Deering KL; Harshaw Q; Phillips A; Harbour M
J Manag Care Spec Pharm; 2022 Oct; 28(10):1180-1189. PubMed ID: 35939048
[No Abstract] [Full Text] [Related]
16. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population.
To TM; Exuzides A; Abbass IM; Patel AM; Ta JT; Surinach A; Fuller RLM; Luo J
J Manag Care Spec Pharm; 2022 Nov; 28(11):1228-1239. PubMed ID: 36282937
[No Abstract] [Full Text] [Related]
17. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis.
Hutson TE; Liu FX; Dieyi C; Kim R; Krulewicz S; Kasturi V; Bhanegaonkar A
J Manag Care Spec Pharm; 2021 Sep; 27(9):1171-1181. PubMed ID: 34165322
[No Abstract] [Full Text] [Related]
18. The cost impact of disease progression to metastatic castration-sensitive prostate cancer.
Trinh QD; Chaves LP; Feng Q; Zhu J; Sandin R; Abbott T
J Manag Care Spec Pharm; 2022 May; 28(5):544-554. PubMed ID: 35471070
[No Abstract] [Full Text] [Related]
19. Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data.
Choong CK; Ford JH; Nyhuis AW; Robinson RL; Aurora SK
J Manag Care Spec Pharm; 2018 Sep; 24(9):921-928. PubMed ID: 30156448
[TBL] [Abstract][Full Text] [Related]
20. Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.
Schultz NM; Penson DF; Wilson SD; Song Y; Yang H; Ramaswamy K; Lowentritt B
J Manag Care Spec Pharm; 2019 Aug; 25(8):889-897. PubMed ID: 31172866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
